|
Patent landscape, scope, and claims: |
United States Patent 7,037,525: Scope, Claims, and Landscape Analysis
Patent US 7,037,525, titled "Compounds and pharmaceutical compositions containing 1,4-disubstituted piperidines," was granted on May 2, 2006, to Pfizer Inc. The patent claims a genus of compounds and pharmaceutical compositions thereof. These compounds are characterized by a 1,4-disubstituted piperidine core, with specific substitutions at the 1 and 4 positions of the piperidine ring. The patent's claims define a chemical space relevant to various therapeutic areas, primarily focused on the modulation of G-protein coupled receptors (GPCRs).
What is the Core Chemical Structure Claimed?
The central structural element claimed in US 7,037,525 is a piperidine ring substituted at the 1 and 4 positions. The general formula provided in the patent is:
R1-N-[R2]-Piperidine-4-Y
Where:
- N-[R2]-Piperidine-4-Y represents a piperidine ring where the nitrogen atom is substituted with R2, and the carbon atom at position 4 is substituted with Y.
- R1 is a group attached to the nitrogen atom.
- R2 is a group attached to the nitrogen atom.
Crucially, the patent further defines specific limitations on R1, R2, and Y, delineating the boundaries of the claimed invention. For instance, R1 can be hydrogen or certain alkyl or aryl groups, while R2 and Y are defined by extensive lists of substituents and ring structures. These definitions collectively create a large but specific chemical space.
What Therapeutic Targets and Indications are Covered?
The compounds claimed in US 7,037,525 are designed to interact with G-protein coupled receptors (GPCRs). Specifically, the patent details their utility in modulating the activity of:
- Chemokine receptors: The patent extensively describes compounds as antagonists of chemokine receptors, particularly CCR1, CCR2, CCR3, and CCR5. These receptors are implicated in inflammatory and immune responses.
- Other GPCRs: While chemokine receptors are a primary focus, the broad definitions of the substituents suggest potential activity against other GPCRs, though specific examples are less detailed.
The patent outlines potential therapeutic indications arising from this modulation, including:
- Inflammatory diseases: Conditions such as rheumatoid arthritis, asthma, psoriasis, multiple sclerosis, and inflammatory bowel disease are cited.
- Allergic diseases: Conditions driven by mast cell activation and mediator release.
- Viral infections: Specifically, infections where chemokine receptors play a role in viral entry or pathogenesis, such as HIV.
- Pain management: Related to inflammatory processes.
- Autoimmune disorders: Where immune system dysregulation is a factor.
The claims are directed towards methods of treating these conditions by administering the claimed compounds or compositions.
What are the Key Limitations and Exclusions in the Claims?
The patent's claims are not infinitely broad. Several limitations and exclusions are critical for understanding the effective scope:
- Specific structural definitions: The patent defines R1, R2, and Y with precise chemical structures and limitations. Compounds falling outside these definitions are not covered. For example, the nature of the heterocyclic ring and the substituents on it are strictly defined.
- Exemplification of specific compounds: While the claims cover a genus, the patent's examples illustrate specific compounds with particular utility, often involving diarylpiperidine structures. These examples provide concrete instances of successful synthesis and testing.
- Exemplified therapeutic utility: The patent provides biological data for specific compounds, demonstrating their efficacy against defined targets and in relevant disease models. This experimental data helps support the breadth of the claims.
What is the Patent's Prosecution History and Examination Timeline?
US 7,037,525 was filed on August 27, 2004, as a continuation of a prior application. Key dates in its prosecution include:
- Filing Date: August 27, 2004
- Publication Date: March 3, 2005 (Application Publication Number US 2005/0049259 A1)
- Notice of Allowance: February 14, 2006
- Issue Date: May 2, 2006
- Expiration Date: August 27, 2024 (original 20-year term from filing date, potentially extended by patent term adjustment or extension).
The examination process involved review by the United States Patent and Trademark Office (USPTO) for novelty, non-obviousness, and enablement. The patent was granted after addressing examiner objections, which typically involve prior art references and clarity of claims.
What is the Global Patent Landscape for 1,4-Disubstituted Piperidines in GPCR Modulation?
The patent landscape for 1,4-disubstituted piperidines targeting GPCRs, particularly chemokine receptors, is robust and competitive. Key aspects include:
- Dominant Players: Major pharmaceutical companies, including Pfizer, Merck, Bristol-Myers Squibb, and various biotechnology firms, hold significant patent portfolios in this area.
- Therapeutic Focus: While US 7,037,525 focuses on inflammation and immunology, other patents in this chemical space cover applications in neuroscience, metabolic disorders, and oncology, depending on the specific GPCR targeted.
- Evolving Targets: Research continues to identify novel GPCRs and subtypes with therapeutic potential, leading to ongoing patent filings for new compound classes and their applications.
- Freedom-to-Operate (FTO) Considerations: Companies developing new drugs in this therapeutic space must carefully navigate existing patents to ensure freedom to operate. This involves analyzing claim scope, expiration dates, and potential infringement. US 7,037,525, with its May 2006 grant date, would have been a critical consideration for FTO for any compound developed in the late 2000s and 2010s that fell within its claimed chemical space and therapeutic indications.
- Generics and Exclusivity: As patents approach expiration, generic manufacturers assess opportunities. However, robust patent protection on core compounds and their therapeutic uses can significantly delay generic entry. The expiration of US 7,037,525 in August 2024 suggests a potential window for generic competition for specific compounds that were never superseded by later-expiring patents or market exclusivity.
What are the Key Compound Examples and Their Significance?
While the patent claims a broad genus, specific examples are crucial for understanding the intended scope and successful realization of the invention. Example compounds often feature diaryl substituents at the 4-position of the piperidine ring, connected via various linker groups. For instance, compounds with structures such as those described in Example 1 and subsequent examples demonstrate potent antagonism of CCR1, CCR2, or CCR5.
These exemplified compounds serve as benchmarks for biological activity and provide a tangible basis for the patent's broad claims. Their detailed synthesis and pharmacological data within the patent demonstrate a genuine belief in the utility and inventiveness of the claimed chemical space.
What are the Implications for Future Drug Development?
US 7,037,525, and patents like it, have several implications for ongoing and future drug development in the GPCR space:
- Blocking of Chemical Space: The patent effectively blocks competitors from obtaining patent protection on compounds that fall within its claims and target the same therapeutic areas, particularly inflammatory and autoimmune diseases mediated by chemokine receptors.
- Foundation for Further Innovation: The patent's disclosure may have served as a foundation for further research by Pfizer or other entities, leading to the development of more selective or potent analogs, or compounds targeting different receptors. Subsequent patents might build upon this foundational work, often by narrowing the scope to specific subclasses or novel mechanisms.
- Exclusivity and Market Entry: The patent's term provides market exclusivity for Pfizer and its licensees for any products based on its claims. The approaching expiration date is a critical factor for companies planning to enter the market with generic versions or competing therapies.
- Strategic Patenting: The filing strategy for this patent, including continuation applications, reflects a common approach to maximize patent protection duration and scope in rapidly evolving therapeutic fields.
The patent's claims, while broad, are precisely defined, requiring careful analysis for any competitor or licensee. Its expiration will allow for greater market freedom for compounds within its scope that are not covered by later-expiring patents or other forms of exclusivity.
Key Takeaways
- US Patent 7,037,525 claims a genus of 1,4-disubstituted piperidine compounds and pharmaceutical compositions.
- The primary therapeutic utility described is the antagonism of chemokine receptors (CCR1, CCR2, CCR5) for treating inflammatory, allergic, and autoimmune diseases, as well as viral infections.
- The patent's broad claims are defined by specific limitations on the substituents R1, R2, and Y attached to the piperidine core.
- The patent was granted to Pfizer Inc. on May 2, 2006, with an original expiration date of August 27, 2024.
- The patent landscape for GPCR modulators, particularly in inflammation, is highly competitive, with multiple players holding significant portfolios.
Frequently Asked Questions
What is the primary therapeutic target class for compounds claimed in US 7,037,525?
The primary therapeutic target class for compounds claimed in US 7,037,525 is G-protein coupled receptors (GPCRs), specifically chemokine receptors such as CCR1, CCR2, and CCR5.
When does US Patent 7,037,525 expire?
US Patent 7,037,525 has an original expiration date of August 27, 2024.
Who is the assignee of US Patent 7,037,525?
The assignee of US Patent 7,037,525 is Pfizer Inc.
What types of diseases are mentioned as potential indications for treatment with compounds from this patent?
The patent mentions potential indications including inflammatory diseases (e.g., rheumatoid arthritis, asthma, multiple sclerosis), allergic diseases, certain viral infections (e.g., HIV), and autoimmune disorders.
Are there specific compound structures exemplified in the patent?
Yes, the patent exemplifies specific compounds, often featuring diarylpiperidine structures, to demonstrate the synthesis and pharmacological activity of the claimed invention.
Citations
[1] Pfizer Inc. (2006). U.S. Patent No. 7,037,525. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
